Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold onto it for at least a few years. Here's why.Vertex is best known for its therapies for the rare lung disease cystic fibrosis (CF). They provide the vast majority of its sales revenue -- which totaled $2.8 billion in the third quarter -- and a significant portion of the programs in its research and development (R&D) pipeline. Its steady work over the year delivered a large market share in CF therapies.Meanwhile, to continue growing, management opted to diversify into new areas. One of those, a program for treating acute pain, could be particularly lucrative. But that prospect is now in question.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool